Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2019 Results Conference Call November 13, 2019 4:30 PM ET
Company Participants
Thomas Gad - Founder, Chairman and President
Claus Moller - Chief Executive Officer
Bo Kruse - Chief Financial Office
Conference Call Participants
Alec Stranahan - Bank of America
Robert Burns - H. C. Wainwright
Boris Peaker - Cowen
Benedict Shim - Canaccord Genuity
Operator
Good day. And welcome to the Y-mAbs Therapeutics, Inc., 2019 Third Quarter Earnings Conference Call. Today's conference is being recorded.
Let me quickly remind you that the following discussion contain certain statements that are considered forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Because forward-looking statements involve risks and uncertainties, they are not guarantees of future performance, and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including those risk factors discussed in the company's prospectus supplement dated October 29, 2019, and filed with the SEC on October 31st, 2019, and the company's Annual Report on Form 10-K for the fiscal year ended December 31st, 2018, as filed with the SEC on March 22, 2019.
At this time, I would like to turn the conference over to Thomas Gad, the Company's Founder, Chairman, and President. Please go ahead, sir.
Thomas Gad
Thank you, Doug. Hello, everyone. And welcome to our third quarter earnings call. Today, we're going to hear remarks from our Chief Executive Officer, Dr. Claus Moller, and as well as our Chief Financial Officer, Bo Kruse.
We ended the third quarter with $98.2 million in cash. As you all know in late October, we completed an oversubscribed secondary offering, which was led by Morgan Stanley, J.P. Morgan, and BAML, in which we sold approximately 5.1 million shares of our common stock, which included the full exercise of the over-allotment option
- Read more current YMAB analysis and news
- View all earnings call transcripts